We evaluated perioperative bleeding after CABG in patients preoperatively treated with ticagrelor or clopidogrel, stratified by discontinuation of these P2Y12inhibitors.
All patients from the prospective, European multicenter registry on Coronary Artery Bypass Grafting (E-CABG) treated with ticagrelor or clopidogrel undergoing isolated primary CABG were eligible. Primary outcome measure was severe or massive bleeding defined according to the Universal Definition of Perioperative Bleeding (UDPB), stratified by P2Y12 inhibitor discontinuation. Secondary outcome measures included four additional definitions of major bleeding. Propensity score matching was performed to adjust for differences in pre- and perioperative covariates.